Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclic GMP phosphodiesterase 5 (PDE5) is an enzyme that hydrolyzes cyclic guanosine monophosphate (cGMP), a key intracellular second messenger. It is highly expressed in the corpus cavernosum, retina, and vascular smooth muscle cells. PDE5 regulates vasodilation and smooth muscle relaxation by controlling cGMP levels. Inhibition of PDE5 is the mechanism of action for drugs used to treat erectile dysfunction and pulmonary arterial hypertension.
Selective inhibition of PDE5, leading to increased intracellular cGMP levels.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic GMP phosphodiesterase 5 (PDE5).